Seattle Genetics Announces ADCETRIS Supplemental BLA Accepted for Filing by the FDA
May 14, 2013 at 09:03 AM EDT
Seattle Genetics (NASDAQ: SGEN ) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplement to the Biologics License Application (sBLA) supporting the use of ADCETRIS (brentuximab vedotin) for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma (HL)
